ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF NEUROLOGY
Volume 25, Issue 2, Pages 215-237
Publisher
Wiley
Online
2018-01-20
DOI
10.1111/ene.13536
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New insights into the burden and costs of multiple sclerosis in Europe
- (2017) Gisela Kobelt et al. Multiple Sclerosis Journal
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- New insights into the burden and costs of multiple sclerosis in Europe
- (2017) Gisela Kobelt et al. Multiple Sclerosis Journal
- Predictors of long-term disability accrual in relapse-onset multiple sclerosis
- (2016) Vilija G. Jokubaitis et al. ANNALS OF NEUROLOGY
- Rituximab versus fingolimod after natalizumab in multiple sclerosis patients
- (2016) Peter Alping et al. ANNALS OF NEUROLOGY
- Adapting the nominal group technique for priority setting of evidence-practice gaps in implementation science
- (2016) Nicole M. Rankin et al. BMC Medical Research Methodology
- Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study
- (2016) Susan Friend et al. BMC Neurology
- Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod
- (2016) M. E. Evangelopoulos et al. INTERNATIONAL JOURNAL OF NEUROSCIENCE
- Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation
- (2016) Bianca Weinstock-Guttman et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study
- (2016) Ilya Kister et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis
- (2016) Jordi Río et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Glatiramer acetate during early pregnancy: A prospective cohort study
- (2016) Sandra Herbstritt et al. Multiple Sclerosis Journal
- Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
- (2016) Ralf Gold et al. Multiple Sclerosis Journal
- Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry
- (2016) Sandra Thiel et al. Multiple Sclerosis Journal
- Disease-modifying therapies and infectious risks in multiple sclerosis
- (2016) Alexander Winkelmann et al. Nature Reviews Neurology
- Assessing response to interferon-β in a multicenter dataset of patients with MS
- (2016) Maria Pia Sormani et al. NEUROLOGY
- International Pediatric MS Study Group Global Members Symposium report: Table
- (2016) Evangeline Wassmer et al. NEUROLOGY
- Consensus definitions for pediatric MS and other demyelinating disorders in childhood: Table
- (2016) Marc Tardieu et al. NEUROLOGY
- Long-term safety and efficacy of teriflunomide
- (2016) Paul O'Connor et al. NEUROLOGY
- The 11-year long-term follow-up study from the randomized BENEFIT CIS trial
- (2016) Ludwig Kappos et al. NEUROLOGY
- Pregnancy outcomes in Lebanese women with multiple sclerosis (the LeMS study): a prospective multicentre study
- (2016) Jawad Fares et al. BMJ Open
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
- (2016) Jonathan AC Sterne et al. BMJ-British Medical Journal
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
- (2016) Jonathan AC Sterne et al. BMJ-British Medical Journal
- Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment
- (2016) Stacy Ellen Hatcher et al. JAMA Neurology
- Glatiramer acetate during early pregnancy: A prospective cohort study
- (2016) Sandra Herbstritt et al. Multiple Sclerosis Journal
- Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
- (2016) Ralf Gold et al. Multiple Sclerosis Journal
- Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry
- (2016) Sandra Thiel et al. Multiple Sclerosis Journal
- Defining high, medium and low impact prognostic factors for developing multiple sclerosis
- (2015) Mar Tintore et al. BRAIN
- Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis
- (2015) Pietro Iaffaldano et al. BRAIN
- Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis
- (2015) Adnan M. Subei et al. CNS DRUGS
- Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS)
- (2015) B. Yamout et al. CURRENT MEDICAL RESEARCH AND OPINION
- Validation of 1-year predictive score of long-term response to interferon-β in everyday clinical practice multiple sclerosis patients
- (2015) M. Romeo et al. EUROPEAN JOURNAL OF NEUROLOGY
- Practical recommendations for the process of proposing, planning and writing a neurological management guideline by EAN task forces
- (2015) M. A. Leone et al. EUROPEAN JOURNAL OF NEUROLOGY
- Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
- (2015) Stefan Braune et al. JOURNAL OF NEUROLOGY
- High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991–2010)
- (2015) Elaine Kingwell et al. JOURNAL OF NEUROLOGY
- Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
- (2015) Jeffrey A Cohen et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis
- (2015) J Kuhle et al. Multiple Sclerosis Journal
- MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients
- (2015) Nature Reviews Neurology
- Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial
- (2015) L. Kappos et al. NEUROLOGY
- Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2015) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Utility of the Rio Score and Modified Rio Score in Korean Patients with Multiple Sclerosis
- (2015) Jae-Won Hyun et al. PLoS One
- The indirect costs of multiple sclerosis: systematic review and meta-analysis
- (2015) Ewa Stawowczyk et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis
- (2015) Anna He et al. JAMA Neurology
- Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort
- (2015) Dalia L. Rotstein et al. JAMA Neurology
- A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis
- (2015) J Kuhle et al. Multiple Sclerosis Journal
- What to expect after natalizumab cessation in a real-life setting
- (2014) S. Salhofer-Polanyi et al. ACTA NEUROLOGICA SCANDINAVICA
- Treatment Options to Reduce Disease Activity After Natalizumab: Paradoxical Effects of Corticosteroids
- (2014) Silvia Rossi et al. CNS Neuroscience & Therapeutics
- Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy
- (2014) Simon A. Broadley et al. JOURNAL OF CLINICAL NEUROSCIENCE
- A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
- (2014) T. L. Vollmer et al. JOURNAL OF NEUROLOGY
- Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis
- (2014) A. Gueguen et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Pregnancy outcomes in patients exposed to interferon beta-1b: Table 1
- (2014) Rebecca S Romero et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Management of relapsing–remitting multiple sclerosis in Latin America: Practical recommendations for treatment optimization
- (2014) Jorge Correale et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial
- (2014) Gavin Giovannoni et al. LANCET NEUROLOGY
- Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Aaron E Miller et al. LANCET NEUROLOGY
- Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Significant clinical worsening after natalizumab withdrawal: Predictive factors
- (2014) A Vidal-Jordana et al. Multiple Sclerosis Journal
- Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study
- (2014) Neda Ebrahimi et al. Multiple Sclerosis Journal
- Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE
- (2014) Bernd C Kieseier et al. Multiple Sclerosis Journal
- MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study
- (2014) R. J. Fox et al. NEUROLOGY
- Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis
- (2014) G. Karlsson et al. NEUROLOGY
- Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity
- (2014) P. Browne et al. NEUROLOGY
- Defining the clinical course of multiple sclerosis: The 2013 revisions
- (2014) F. D. Lublin et al. NEUROLOGY
- Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study
- (2014) Niklas Bergvall et al. PLoS One
- Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events
- (2014) P K Coyle et al. BMJ Open
- Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab
- (2014) Marinella Clerico et al. JAMA Neurology
- Switching From Natalizumab to Fingolimod in Multiple Sclerosis
- (2014) Mikael Cohen et al. JAMA Neurology
- Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis
- (2014) Edward Fox et al. Multiple Sclerosis and Related Disorders
- Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients
- (2014) Francesca Sangalli et al. Multiple Sclerosis and Related Disorders
- Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis
- (2013) Omar Khan et al. ANNALS OF NEUROLOGY
- Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS
- (2013) Jeffrey A. Cohen et al. JOURNAL OF NEUROLOGY
- Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
- (2013) G. Edan et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
- (2013) Ralf Gold et al. LANCET
- International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions
- (2013) Lauren B Krupp et al. Multiple Sclerosis Journal
- Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis
- (2013) Luca Prosperini et al. Multiple Sclerosis Journal
- Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
- (2013) Patrick Vermersch et al. Multiple Sclerosis Journal
- Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up
- (2013) Marta Melis et al. NEUROLOGICAL SCIENCES
- Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study
- (2012) Marta Giannini et al. BMC Neurology
- The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis
- (2012) Yara Dadalti Fragoso et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response
- (2012) J. Río et al. EUROPEAN JOURNAL OF NEUROLOGY
- Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis
- (2012) Joachim Havla et al. JOURNAL OF NEUROLOGY
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Switching therapy from natalizumab to fingolimod in relapsing–remitting multiple sclerosis: clinical and magnetic resonance imaging findings
- (2012) F Rinaldi et al. Multiple Sclerosis Journal
- Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome
- (2012) Giancarlo Comi et al. Multiple Sclerosis Journal
- Scoring treatment response in patients with relapsing multiple sclerosis
- (2012) MP Sormani et al. Multiple Sclerosis Journal
- Disease-modifying drugs for multiple sclerosis in pregnancy: A systematic review
- (2012) E. Lu et al. NEUROLOGY
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple sclerosis and pregnancy: experience from a nationwide database in Germany
- (2012) Kerstin Hellwig et al. Therapeutic Advances in Neurological Disorders
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
- (2011) Chris H. Polman et al. ANNALS OF NEUROLOGY
- Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis
- (2011) Carmen Tur ARCHIVES OF NEUROLOGY
- Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study
- (2011) G. Borriello et al. EUROPEAN JOURNAL OF NEUROLOGY
- GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
- (2011) Gordon Guyatt et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study
- (2011) María José Magraner et al. JOURNAL OF NEUROLOGY
- Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study
- (2011) Bhupendra Khatri et al. LANCET NEUROLOGY
- Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial
- (2011) Giancarlo Comi et al. LANCET NEUROLOGY
- Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs
- (2011) E Lu et al. Multiple Sclerosis Journal
- Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosis
- (2011) M Calabrese et al. Multiple Sclerosis Journal
- Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment
- (2011) Kerstin Hellwig et al. Multiple Sclerosis Journal
- Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis
- (2011) Luca Prosperini et al. Multiple Sclerosis Journal
- Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis
- (2011) T Chitnis et al. Multiple Sclerosis Journal
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natalizumab dosage suspension: Are we helping or hurting?
- (2010) Timothy W. West et al. ANNALS OF NEUROLOGY
- Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy
- (2010) Augusto Miravalle et al. ARCHIVES OF NEUROLOGY
- Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial
- (2010) G. C. Ebers et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Observations during an elective interruption of natalizumab treatment: a post-marketing study
- (2010) Giovanna Borriello et al. Multiple Sclerosis Journal
- Pregnancy and fetal outcomes after interferon- exposure in multiple sclerosis
- (2010) M. P. Amato et al. NEUROLOGY
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
- (2010) Gavin Giovannoni et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis
- (2009) L. Prosperini et al. EUROPEAN JOURNAL OF NEUROLOGY
- Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
- (2009) G Comi et al. LANCET
- Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
- (2009) Ludwig Kappos et al. LANCET NEUROLOGY
- 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
- (2009) Paul O'Connor et al. LANCET NEUROLOGY
- Epidemiological characteristics of pregnancy, delivery, and birth outcome in women with multiple sclerosis in Argentina (EMEMAR study)
- (2009) N Fernández Liguori et al. Multiple Sclerosis Journal
- Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study
- (2009) C Weber-Schoendorfer et al. Multiple Sclerosis Journal
- Clinical prognostic factors in multiple sclerosis: a natural history review
- (2009) Alexandra Degenhardt et al. Nature Reviews Neurology
- Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study
- (2009) D. Cadavid et al. NEUROLOGY
- Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?
- (2008) F. Patti et al. JOURNAL OF NEUROLOGY
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
- (2008) Daniel D Mikol et al. LANCET NEUROLOGY
- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
- (2008) Gordon H Guyatt et al. BMJ-British Medical Journal
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started